Biocon Limited has announced its financial results for the second quarter of FY27. The company reported revenues from operations of ₹4,389 crore, with a net profit of ₹41 crore. The presentation covers financial highlights, performance updates for Biosimilars, Generics, and Services segments, and concluding remarks on the outlook for the second half of FY27.
Biocon Limited Q2 FY27 Earnings Call Highlights
Biocon Limited hosted its Q2 FY27 Earnings Call on November 04, 2026, presenting a comprehensive update on its financial performance and business operations. The presentation, submitted to the BSE Limited and the National Stock Exchange of India Limited, detailed the company’s results for the quarter ended September 30, 2026.
Financial Performance Summary
In Q2 FY27, Biocon reported total revenue of ₹4,423 crore, an increase of 1% compared to the previous year. Revenue from operations stood at ₹4,389 crore, also up by 2% year-on-year. EBITDA for the quarter was ₹865 crore, representing a 7% decrease YoY, with a margin of 20%. Net Profit (Reported) was ₹41 crore, a significant decrease of 52% YoY.
For the first half of FY27 (H1 FY27), Total Revenue was ₹8,814 crore, up 5% YoY. Revenue from Operations was ₹8,725 crore, up 6% YoY. EBITDA for H1 FY27 stood at ₹1,767 crore, showing a marginal 0% change YoY, with a margin of 20%. Net Profit (Reported) for H1 FY27 was ₹182 crore, an impressive increase of 57% YoY.
Segmental Performance Updates
Biosimilars
Biosimilars segment revenue for Q2 FY27 was ₹2,809 crore, a 3% increase YoY. EBITDA for the segment was ₹623 crore, down 7% YoY. The company highlighted the encouraging US launch of Yesafili™ and continued strong performance of Yesintek®. The 10-year Brazil Pertuzumab partnership is expected to provide long-term revenue visibility.
Generics
The Generics segment reported revenues of ₹774 crore in Q2 FY27, a growth of 10% YoY. EBITDA margin expanded by over 700bps YoY. Liraglutide is gaining traction, and complex injectables, peptides, and formulations are seen as key drivers for future growth.
Services
Services segment revenue for Q2 FY27 stood at ₹833 crore, an increase of 13% QoQ. EBITDA margin improved by 500bps QoQ. The company noted that FY27 is a transition year for this segment, with further improvements expected in the second half.
Concluding Remarks and Outlook
Biocon anticipates a stronger second half of FY27, driven by momentum in Biosimilars, enhanced insulin capacity, improved Generics profitability, and a progressive recovery in Services. The company remains focused on translating growth into improved margins, free cash flow, debt reduction, and higher returns on capital. Disciplined execution is expected to convert global capabilities and investments into sustainable earnings growth and shareholder value.
Source: BSE
